Paper38176338
Folic acid functionalized gadolinium-doped carbon dots as fluorescence / magnetic resonance imaging contrast agent for targeted imaging of liver cancer.
Du J and 8 others. Colloids Surf B Biointerfaces, 2024. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Folic acid functionalized gadolinium-doped carbon dots as fluorescence / magnetic resonance imaging contrast agent for targeted imaging of liver cancer. Papers, record 38176338. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38176338
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Folic acid functionalized gadolinium-doped carbon dots as fluorescence / magnetic resonance imaging contrast agent for targeted imaging of liver cancer.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Liver Neoplasms | Major topic |
| Quantum Dots | Major topic |
| Animals | |
| Mice | |
| Contrast Media | |
| Fluorescence | |
| Gadolinium | |
| Carbon | |
| Folic Acid | |
| Mice, Nude | |
| Magnetic Resonance Imaging |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42567852 | Exploring the in-vitro evaluation of folic acid-modified gadolinium nanoparticles in HEK-293, HeLa, and KB cancer cells for targeted-MR-imaging agent candidate. | Sci Rep | 2026 | https://conductscience.org/library/papers/42567852 | PubMed |
| 42340548 | Biomass derived carbon dots from green synthesis to multimodal bioimaging applications. | Discov Nano | 2026 | https://conductscience.org/library/papers/42340548 | PubMed |
| 42290971 | Materialogenetics: an emerging and promising framework for cell-specific genetic manipulation. | Bioact Mater | 2026 | https://conductscience.org/library/papers/42290971 | PubMed |
| 42094738 | From Bench to Bedside: Multifunctional Nanoplatforms in the Fight Against Non-alcoholic Fatty Liver Disease. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42094738 | PubMed |
| 41723470 | Cell membranes-encapsulated gadolinium-doped carbon dots for the efficient photothermal and immunotherapeutic synergistic treatment of hepatocellular carcinoma. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41723470 | PubMed |
| 41597259 | Advancing Bioconjugated Quantum Dots with Click Chemistry and Artificial Intelligence to Image and Treat Glioblastoma. | Cells | 2026 | https://conductscience.org/library/papers/41597259 | PubMed |
| 40452787 | Construction of Cationic Carbon Dots Carrying Survivin siRNA Delivery System and Its Active Targeting Therapy for Liver Cancer. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40452787 | PubMed |
| 39339503 | Engineering of Green Carbon Dots for Biomedical and Biotechnological Applications. | Molecules | 2024 | https://conductscience.org/library/papers/39339503 | PubMed |
| 39296941 | The Current Status and Future Directions on Nanoparticles for Tumor Molecular Imaging. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/39296941 | PubMed |
| 39275059 | Carbon Dots: A Versatile Platform for Cu2+ Detection, Anti-Counterfeiting, and Bioimaging. | Molecules | 2024 | https://conductscience.org/library/papers/39275059 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38176338
GET https://conductscience.org/api/papers/v1/38176338/authors